Detail akcie Jazz Pharma online

Business Summary: Jazz Pharmaceuticals plc is a global biopharmaceutical company. It is engaged in developing medicines for people with serious diseases, often with limited or no therapeutic options. It has a diverse portfolio of marketed medicines, including therapies for sleep disorders and epilepsy, and a portfolio of cancer treatments. Its lead-marketed products include Xywav (calcium, magnesium, potassium, and sodium oxybates) oral solution, Epidiolex (cannabidiol) oral solution, Rylaze (asparaginase erwinia chrysanthemi (recombinant)-rywn), Zepzelca (lurbinectedin), Ziihera (zanidatamab-hrii), and Enrylaze (recombinant crisantaspase). Its product candidates include Zanidatamab, Vyxeos, JZP815, JZP898, JZP441, and others. Xywav is used for the treatment of cataplexy or EDS in patients seven years of age and older with narcolepsy. The Company, through Chimerix, Inc., also owns a clinical asset, dordaviprone, a novel small molecule treatment in development for H3 K27M-mutant diffuse glioma.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2024, Jazz Pharmaceuticals PLC revenues increased 6% to $4.07B. Net income increased 35% to $560.1M. Revenues reflect Xywav segment increase of 16% to $1.47B, High-sodium oxybate AG royalty revenue segment increase from $75.9M to $217.6M, United States segment increase of 5% to $3.66B, Europe segment increase of 16% to $312.7M. Net income benefited from Interest income increase of 63% to $106.3M (income).